|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: Oncogene or a tumor suppressor? Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee RC, Feinbaum RL and Ambros V: The
C. elegans heterochronic gene lin-4 encodes small RNAs with
antisense complementarity to lin-14. Cell. 75:843–854. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fire A, Xu S, Montgomery MK, Kostas SA,
Driver SE and Mello CC: Potent and specific genetic interference by
double-stranded RNA in Caenorhabditis elegans. Nature.
391:806–811. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kozomara A, Birgaoanu M and
Griffiths-Jones S: miRBase: From microRNA sequences to function.
Nucleic Acids Res. 47:D155–D162. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Joyce BT, Zheng Y, Zhang Z, Liu L,
Kocherginsky M, Murphy R, Achenbach CJ, Musa J, Wehbe F, Just A, et
al: miRNA-processing gene methylation and cancer risk. Cancer
Epidemiol Biomarkers Prev. 27:550–557. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang G, Xiong G, Cao Z, Zheng S, You L,
Zhang T and Zhao Y: miR-497 expression, function and clinical
application in cancer. Oncotarget. 7:55900–55911. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Menigatti M, Staiano T, Manser CN,
Bauerfeind P, Komljenovic A, Robinson M, Jiricny J, Buffoli F and
Marra G: Epigenetic silencing of monoallelically methylated miRNA
loci in precancerous colorectal lesions. Oncogenesis. 2:e562013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Itesako T, Seki N, Yoshino H, Chiyomaru T,
Yamasaki T, Hidaka H, Yonezawa T, Nohata N, Kinoshita T, Nakagawa M
and Enokida H: The microRNA expression signature of bladder cancer
by deep sequencing: The functional significance of the miR-195/497
cluster. PLoS One. 9:e843112014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang W, Danaher RJ, Miller CS, Berger JR,
Nubia VG, Wilfred BS, Neltner JH, Norris CM and Nelson PT:
Expression of miR-15/107 family microRNAs in human tissues and
cultured rat brain cells. Genomics Proteomics Bioinformatics.
12:19–30. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Yan L, Huang X, Shao Q, Huang M, Deng L,
Wu Q, Zeng Y and Shao J: MicroRNA miR-21 overexpression in human
breast cancer is associated with advanced clinical stage, lymph
node metastasis and patient poor prognosis. RNA. 14:2348–2360.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guo J, Miao Y, Xiao B, Huan R, Jiang Z,
Meng D and Wang Y: Differential expression of microRNA species in
human gastric cancer versus non-tumorous tissues. J Gastroen
Hepatol. 24:652–657. 2009. View Article : Google Scholar
|
|
13
|
Flavin RJ, Smyth PC, Laios A, O'Toole SA,
Barrett C, Finn SP, Russell S, Ring M, Denning KM, Li J, et al:
Potentially important microRNA cluster on chromosome 17p13.1 in
primary peritoneal carcinoma. Mod Pathol. 22:197–205. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Özata DM, Caramuta S, Velázquez-Fernández
D, Akçakaya P, Xie H, Höög A, Zedenius J, Bäckdahl M, Larsson C and
Lui W: The role of microRNA deregulation in the pathogenesis of
adrenocortical carcinoma. Endocr-Relat Cancer. 18:643–655. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Caramuta S, Lee L, Ozata DM, Akçakaya P,
Xie H, Höög A, Zedenius J, Bäckdahl M, Larsson C and Lui WO:
Clinical and functional impact of TARBP2 over-expression in
adrenocortical carcinoma. Endocr Relat Cancer. 20:551–564. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yang C, Wang C, Chen X, Chen S, Zhang Y,
Zhi F, Wang J, Li L, Zhou X, Li N, et al: Identification of seven
serum microRNAs from a genome-wide serum microRNA expression
profile as potential noninvasive biomarkers for malignant
astrocytomas. Int J Cancer. 132:116–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Guo ST, Jiang CC, Wang GP, Li YP, Wang CY,
Guo XY, Yang RH, Feng Y, Wang FH, Tseng HY, et al: MicroRNA-497
targets insulin-like growth factor 1 receptor and has a tumour
suppressive role in human colorectal cancer. Oncogene.
32:1910–1920. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang L, Jiang CF, Li DM, Ge X, Shi ZM, Li
CY, Liu X, Yin Y, Zhen L, Liu LZ and Jiang BH: MicroRNA-497
inhibits tumor growth and increases chemosensitivity to
5-fluorouracil treatment by targeting KSR1. Oncotarget.
7:2660–2671. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhang N, Shen Q and Zhang P: miR-497
suppresses epithelial-mesenchymal transition and metastasis in
colorectal cancer cells by targeting fos-related antigen-1. Onco
Targets Ther. 9:6597–6604. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu Y, Chen J, Gao C, Zhu D, Xu X, Wu C and
Jiang J: MicroRNA-497 inhibits tumor growth through targeting
insulin receptor substrate 1 in colorectal cancer. Oncol Lett.
14:6379–6386. 2017.PubMed/NCBI
|
|
21
|
Hong S, Yan Z, Wang H, Ding L and Bi M:
Up-regulation of microRNA-497-5p inhibits colorectal cancer cell
proliferation and invasion via targeting PTPN3. Biosci Rep.
39:BSR201911232019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Namløs HM, Meza-Zepeda LA, Barøy T,
Østensen IHG, Kresse SH, Kuijjer ML, Serra M, Bürger H,
Cleton-Jansen AM and Myklebost O: Modulation of the osteosarcoma
expression phenotype by microRNAs. PLoS One. 7:e480862012.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Luo M, Shen D, Zhou X, Chen X and Wang W:
MicroRNA-497 is a potential prognostic marker in human cervical
cancer and functions as a tumor suppressor by targeting the
insulin-like growth factor 1 receptor. Surgery. 153:836–847. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xie Y, Wei RR, Huang GL, Zhang MY, Yuan YF
and Wang HY: Checkpoint kinase 1 is negatively regulated by miR-497
in hepatocellular carcinoma. Med Oncol. 31:8442014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He XX, Kuang SZ, Liao JZ, Xu CR, Chang Y,
Wu YL, Gong J, Tian DA, Guo AY and Lin JS: The regulation of
microRNA expression by DNA methylation in hepatocellular carcinoma.
Mol Biosyst. 11:532–539. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Furuta M, Kozaki K, Tanimoto K, Tanaka S,
Arii S, Shimamura T, Niida A, Miyano S and Inazawa J: The
tumor-suppressive miR-497-195 cluster targets multiple cell-cycle
regulators in hepatocellular carcinoma. PLoS One. 8:e601552013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yan JJ, Zhang YN, Liao JZ, Ke KP, Chang Y,
Li PY, Wang M, Lin JS and He XX: miR-497 suppresses angiogenesis
and metastasis of hepatocellular carcinoma by inhibiting VEGFA and
AEG-1. Oncotarget. 6:29527–29542. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ding Q, He K, Luo T, Deng Y, Wang H, Liu
H, Zhang J, Chen K, Xiao J, Duan X, et al: SSRP1 contributes to the
malignancy of hepatocellular carcinoma and is negatively regulated
by miR-497. Mol Ther. 24:903–914. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shen L, Li J, Xu L, Ma J, Li H, Xiao X,
Zhao J and Fang L: miR-497 induces apoptosis of breast cancer cells
by targeting Bcl-w. Exp Ther Med. 3:475–480. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang
Y, Zou C, Zhang X, Liu S, Wang X, et al: Analysis of miR-195 and
miR-497 expression, regulation and role in breast cancer. Clin
Cancer Res. 17:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wei C, Luo Q, Sun X, Li D, Song H, Li X,
Song J, Hua K and Fang L: MicroRNA-497 induces cell apoptosis by
negatively regulating Bcl-2 protein expression at the
posttranscriptional level in human breast cancer. Int J Clin Exp
Pathol. 8:7729–7739. 2015.PubMed/NCBI
|
|
32
|
Creevey L, Ryan J, Harvey H, Bray IM,
Meehan M, Khan AR and Stallings RL: MicroRNA-497 increases
apoptosis in MYCN amplified neuroblastoma cells by targeting the
key cell cycle regulator WEE1. Mol Cancer. 12:232013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao WY, Wang Y, An ZJ, Shi CG, Zhu GA,
Wang B, Lu MY, Pan CK and Chen P: Downregulation of miR-497
promotes tumor growth and angiogenesis by targeting HDGF in
non-small cell lung cancer. Biochem Biophys Res Commun.
435:466–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yin Q, Han Y, Zhu D, Li Z, Shan S, Jin W,
Lu Q and Ren T: miR-145 and miR-497 suppress TGF-β-induced
epithelial-mesenchymal transition of non-small cell lung cancer by
targeting MTDH. Cancer Cell Int. 18:1052018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Huang X, Wang L, Liu W and Li F:
MicroRNA-497-5p inhibits proliferation and invasion of non-small
cell lung cancer by regulating FGF2. Oncol Lett. 17:3425–3431.
2019.PubMed/NCBI
|
|
36
|
Li W, Jin X, Deng X, Zhang G, Zhang B and
Ma L: The putative tumor suppressor microRNA-497 modulates gastric
cancer cell proliferation and invasion by repressing eIF4E. Biochem
Biophys Res Commun. 449:235–240. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Xie G, Ke Q, Ji YZ, Wang AQ, Jing M and
Zou LL: FGFR1 is an independent prognostic factor and can be
regulated by miR-497 in gastric cancer progression. Braz J Med Biol
Res. 52:e78162018. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Feng L, Cheng K, Zang R, Wang Q and Wang
J: miR-497-5p inhibits gastric cancer cell proliferation and growth
through targeting PDK3. Biosci Rep. 39:BSR201906542019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang W, Ren F, Wu Q, Jiang D, Li H, Peng
Z, Wang J and Shi H: MicroRNA-497 inhibition of ovarian cancer cell
migration and invasion through targeting of SMAD specific E3
ubiquitin protein ligase 1. Biochem Biophys Res Commun.
449:432–437. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang S, Mo Y, Midorikawa K, Zhang Z, Huang
G, Ma N, Zhao W, Hiraku Y, Oikawa S and Murata M: The potent tumor
suppressor miR-497 inhibits cancer phenotypes in nasopharyngeal
carcinoma by targeting ANLN and HSPA4L. Oncotarget. 6:35893–35907.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ruan WD, Wang P, Feng S, Xue Y and Zhang
B: MicroRNA-497 inhibits cell proliferation, migration, and
invasion by targeting AMOT in human osteosarcoma cells. Onco
Targets Ther. 9:303–313. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Sun Z, Li A, Yu Z, Li X, Guo X and Chen R:
MicroRNA-497-5p suppresses tumor cell growth of osteosarcoma by
targeting ADP ribosylation factor-like protein 2. Cancer Biother
Radiopharm. 32:371–378. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen Y, Kuang D, Zhao X, Chen D, Wang X,
Yang Q, Wan J, Zhu Y, Wang Y, Zhang S, et al: miR-497-5p inhibits
cell proliferation and invasion by targeting KCa3.1 in
angiosarcoma. Oncotarget. 7:58148–58161. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yang H, Wu XL, Wu KH, Zhang R, Ju LL, Ji
Y, Zhang YW, Xue SL, Zhang YX, Yang YF, et al: MicroRNA-497
regulates cisplatin chemosensitivity of cervical cancer by
targeting transketolase. Am J Cancer Res. 6:2690–2699.
2016.PubMed/NCBI
|
|
45
|
Chen Y, Du J, Wang Y, Shi H, Jiang Q,
Wang' Y, Zhang H, Wei Y, Xue W, Pu Z, et al: MicroRNA-497-5p
induces cell cycle arrest of cervical cancer cells in s phase by
targeting CBX4. Onco Targets Ther. 12:10535–10545. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wang P, Meng X, Huang Y, Lv Z, Liu J, Wang
G, Meng W, Xue S, Zhang Q, Zhang P, et al: MicroRNA-497 inhibits
thyroid cancer tumor growth and invasion by suppressing BDNF.
Oncotarget. 8:2825–2834. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhuang J, Ye Y, Wang G, Ni J, He S, Hu C,
Xia W and Lv Z: MicroRNA-497 inhibits cellular proliferation,
migration and invasion of papillary thyroid cancer by directly
targeting AKT3. Mol Med Rep. 16:5815–5822. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Mizrahi A, Barzilai A, Gur-Wahnon D,
Ben-Dov IZ, Glassberg S, Meningher T, Elharar E, Masalha M,
Jacob-Hirsch J, Tabibian-Keissar H, et al: Alterations of microRNAs
throughout the malignant evolution of cutaneous squamous cell
carcinoma: The role of miR-497 in epithelial to mesenchymal
transition of keratinocytes. Oncogene. 37:218–230. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wei XH, Gu XL, Zhou XT, Ma M and Lou CX:
miR-497 promotes the progression of cutaneous squamous cell
carcinoma through FAM114A2. Eur Rev Med Pharmacol Sci.
22:7348–7355. 2018.PubMed/NCBI
|
|
50
|
Chai L, Kang XJ, Sun ZZ, Zeng MF, Yu SR,
Ding Y, Liang JQ, Li TT and Zhao J: miR-497-5p, miR-195-5p and
miR-455-3p function as tumor suppressors by targeting hTERT in
melanoma A375 cells. Cancer Manag Res. 10:989–1003. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lu F, Ye Y, Zhang H, He X, Sun X, Yao C,
Mao H, He X, Qian C, Wang B, et al: miR-497/Wnt3a/c-jun feedback
loop regulates growth and epithelial-to-mesenchymal transition
phenotype in glioma cells. Int J Biol Macromol. 120:985–991. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Qu F, Ye J, Pan X, Wang J, Gan S, Chu C,
Chu J, Zhang X, Liu M, He H and Cui X: MicroRNA-497-5p
down-regulation increases PD-L1 expression in clear cell renal cell
carcinoma. J Drug Target. 27:67–74. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hoareau-Aveilla C, Quelen C, Congras A,
Caillet N, Labourdette D, Dozier C, Brousset P, Lamant L and
Meggetto F: miR-497 suppresses cycle progression through an axis
involving CDK6 in ALK-positive cells. Haematologica. 104:347–359.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Wang L, Li K, Lin X, Yao Z, Wang S, Xiong
X, Ning Z, Wang J, Xu X, Jiang Y, et al: Metformin induces human
esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1
axis. Cancer Lett. 450:22–31. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Zhang Y, Zhu Z, Huang S, Zhao Q, Huang C,
Tang Y, Sun C, Zhang Z, Wang L, Chen H, et al: lncRNA XIST
regulates proliferation and migration of hepatocellular carcinoma
cells by acting as miR-497-5p molecular sponge and targeting PDCD4.
Cancer Cell Int. 19:1982019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Maura F, Cutrona G, Mosca L, Matis S,
Lionetti M, Fabris S, Agnelli L, Colombo M, Massucco C, Ferracin M,
et al: Association between gene and miRNA expression profiles and
stereotyped subset #4 B-cell receptor in chronic lymphocytic
leukemia. Leuk Lymphoma. 56:3150–3158. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wald AI, Hoskins EE, Wells SI, Ferris RL
and Khan SA: Alteration of microRNA profiles in squamous cell
carcinoma of the head and neck cell lines by human papillomavirus.
Head Neck. 33:504–512. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Matsuyama H and Suzuki HI: Systems and
synthetic microRNA biology: From biogenesis to disease
pathogenesis. Int J Mol Sci. 21:1322019. View Article : Google Scholar
|
|
59
|
Daura-Oller E, Cabre M, Montero MA,
Paternain JL and Romeu A: Specific gene hypomethylation and cancer:
New insights into coding region feature trends. Bioinformation.
3:340–343. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Esteller M: Relevance of DNA methylation
in the management of cancer. Lancet Oncol. 4:351–358. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Zhang X, Wang W, Zhu W, Dong J, Cheng Y,
Yin Z and Shen F: Mechanisms and functions of long non-coding RNAs
at multiple regulatory levels. Int Mol Sci. 20:55732019. View Article : Google Scholar
|
|
62
|
Loda A and Heard E: Xist RNA in action:
Past, present, and future. PLoS Genet. 15:e10083332019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yang Z, Jiang X, Jiang X and Zhao H:
X-inactive-specific transcript: A long noncoding RNA with complex
roles in human cancers. Gene. 679:28–35. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Ma L, Zhou Y, Luo X, Gao H, Deng X and
Jiang Y: Long non-coding RNA XIST promotes cell growth and invasion
through regulating miR-497/MACC1 axis in gastric cancer.
Oncotarget. 8:4125–4135. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Li M, Tang X, Fu Y, Wang T and Zhu J:
Regulatory mechanisms and clinical applications of the long
non-coding RNA PVT1 in cancer treatment. Front Oncol. 9:7872019.
View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Song J, Wu X, Liu F, Li M, Sun Y, Wang Y,
Wang C, Zhu K, Jia X, Wang B and Ma X: Long non-coding RNA PVT1
promotes glycolysis and tumor progression by regulating miR-497/HK2
axis in osteosarcoma. Biochem Biophys Res Commun. 490:217–2124.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Guo D, Wang Y, Ren K and Han X: Knockdown
of LncRNA PVT1 inhibits tumorigenesis in non-small-cell lung cancer
by regulating miR-497 expression. Exp Cell Res. 362:172–179. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Feng L, Zhu Y, Zhang Y and Rao M: LncRNA
GACAT3 promotes gastric cancer progression by negatively regulating
miR-497 expression. Biomed Pharmacother. 97:136–142. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Zhong H, Yang J, Zhang B, Wang X, Pei L,
Zhang L, Lin Z, Wang Y and Wang C: LncRNA GACAT3 predicts poor
prognosis and promotes cell proliferation in breast cancer through
regulation of miR-497/CCND2. Cancer Biomark. 22:787–797. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Xia T, Chen J, Wu K, Zhang J and Yan Q:
Long noncoding RNA NEAT1 promotes the growth of gastric cancer
cells by regulating miR-497-5p/PIK3R1 axis. Eur Rev Med Pharmacol
Sci. 23:6914–6926. 2019.PubMed/NCBI
|
|
71
|
Sun Z, Guo X, Zang M, Wang P, Xue S and
Chen G: Long non-coding RNA LINC00152 promotes cell growth and
invasion of papillary thyroid carcinoma by regulating the
miR-497/BDNF axis. J Cell Physiol. 234:1336–1345. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Yu T, Xu Z, Zhang X, Men L and Nie H: Long
intergenic non-protein coding RNA 152 promotes multiple myeloma
progression by negatively regulating microRNA-497. Oncol Rep.
40:3763–3771. 2018.PubMed/NCBI
|
|
73
|
Xu D, Chen Y, Yuan C, Zhang S and Peng W:
Long non-coding RNA LINC00662 promotes proliferation and migration
in oral squamous cell carcinoma. Onco Targets Ther. 12:647–656.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Liu Z, Yao Y, Huang S, Li L, Jiang B, Guo
H, Lei W, Xiong J and Deng J: LINC00662 promotes gastric cancer
cell growth by modulating the Hippo-YAP1 pathway. Biochem Bioph Res
Commun. 505:843–859. 2018. View Article : Google Scholar
|
|
75
|
Xu X, Gu J, Ding X, Ge G, Zang X, Ji R,
Shao M, Mao Z, Zhang Y, Zhang J, et al: LINC00978 promotes the
progression of hepatocellular carcinoma by regulating EZH2-mediated
silencing of p21 and E-cadherin expression. Cell Death Dis.
10:7522019. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Bu J, Lv W, Liao Y, Xiao X and Lv B: Long
non-coding RNA LINC00978 promotes cell proliferation and
tumorigenesis via regulating microRNA-497/NTRK3 axis in gastric
cancer. Int J Biol Macromol. 123:1106–1114. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Dong B, Chen X, Zhang Y, Zhu C and Dong Q:
The prognostic value of lncRNA SNHG1 in cancer patients: A
meta-analysis. BMC Cancer. 19:7802019. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Li Z, Lu Q, Zhu D, Han Y, Zhou X and Ren
T: Lnc-SNHG1 may promote the progression of non-small cell lung
cancer by acting as a sponge of miR-497. Biochem Bioph Res Commun.
506:632–640. 2018. View Article : Google Scholar
|
|
79
|
Bai J, Xu J, Zhao J and Zhang R: lncRNA
SNHG1 cooperated with miR-497/miR-195-5p to modify
epithelial-mesenchymal transition underlying colorectal cancer
exacerbation. J Cell Physiol. 235:1453–1468. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Christensen LL, True K, Hamilton MP,
Nielsen MM, Damas ND, Damgaard CK, Ongen H, Dermitzakis E, Bramsen
JB, Pedersen JS, et al: SNHG16 is regulated by the Wnt pathway in
colorectal cancer and affects genes involved in lipid metabolism.
Mol Oncol. 10:1266–1282. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Wen Q, Zhao L, Wang T, Lv N, Cheng X,
Zhang G and Bai L: LncRNA SNHG16 drives proliferation and invasion
of papillary thyroid cancer through modulation of miR-497. Onco
Targets Ther. 12:699–708. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Zhu Q, Li Y, Guo Y, Hu L, Xiao Z, Liu X,
Wang J, Xu Q and Tong X: Long non-coding RNA SNHG16 promotes
proliferation and inhibits apoptosis of diffuse large B-cell
lymphoma cells by targeting miR-497-5p/PIM1 axis. J Cell Mol Med.
23:7395–7405. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Liu N, Wang Z, Liu D and Xie P:
HOXC13-AS-miR-122-5p-SATB1-C-Myc feedback loop promotes migration,
invasion and EMT process in glioma. Onco Targets Ther.
12:7165–7173. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Li X, Wang Q, Rui Y, Zhang C, Wang W, Gu
J, Tang J and Ding Y: HOXC13-AS promotes breast cancer cell growth
through regulating miR-497-5p/PTEN axis. J Cell Physiol.
234:22343–22351. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Zhang L, Wang Y, Li X, Xia X, Li N, He R,
He H, Han C and Zhao W: ZBTB7A Enhances Osteosarcoma
Chemoresistance by Transcriptionally Repressing
lncRNALINC00473-IL24 Activity. Neoplasia. 19:908–918. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Bai J, Zhao W, Li W, Ying Z and Jiang D:
Long noncoding RNA LINC00473 indicates a poor prognosis of breast
cancer and accelerates tumor carcinogenesis by competing endogenous
sponging miR-497. Eur Rev Med Pharmaco. 23:3410–3420. 2019.
|
|
87
|
He Z: LINC00473/miR-497-5p regulates
esophageal squamous cell carcinoma progression through targeting
PRKAA1. Cancer Biother Radiopharm. 34:650–659. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Li Z, Zhu Q, Zhang H, Hu Y, Wang G and Zhu
Y: MALAT1: A potential biomarker in cancer. Cancer Manag Res.
10:6757–6768. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Hassan N, Zhao J, Glover A, Robinson BG
and Sidhu SB: Reciprocal interplay of miR-497 and MALAT1 promotes
tumourigenesis of adrenocortical cancer. Endocr Relat Cancer.
26:677–688. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Zhao P, Guan H, Dai Z, Ma Y, Zhao Y and
Liu D: Long noncoding RNA DLX6-AS1 promotes breast cancer
progression via miR-505-3p/RUNX2 axis. Eur J Pharmacol.
865:1727782019. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Yang J, Ye Z, Mei D, Gu H and Zhang J:
Long noncoding RNA DLX6-AS1 promotes tumorigenesis by modulating
miR-497-5p/FZD4/FZD6/Wnt/β-catenin pathway in pancreatic cancer.
Cancer Manag Res. 11:4209–4221. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Zhang R, Hao S, Yang L, Xie J, Chen S and
Gu G: LINC00339 promotes cell proliferation and metastasis in
pancreatic cancer via miR-497-5p/IGF1R axis. J BUON. 24:729–738.
2019.PubMed/NCBI
|
|
93
|
Zhang J, Chen Z, Chen D, Tian X, Wang C,
Zhou Z, Gao Y, Xu Y, Chen C, Zheng Z, et al:
LINC01410-miR-532-NCF2-NF-kB feedback loop promotes gastric cancer
angiogenesis and metastasis. Oncogene. 37:2660–2675. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Cai M, Xu L, Shen L and Zhang J: The
expression of long non-coding RNA-LINC01410 in pancreatic cancer
and its effect on proliferation and migration of pancreatic cancer
cells. Zhonghua Yi Xue Za Zhi. 99:1406–1411. 2019.(In Chinese).
PubMed/NCBI
|
|
95
|
Yu C and Zhang F: LncRNA AC009022.1
enhances colorectal cancer cells proliferation, migration, and
invasion by promoting ACTR3B expression via suppressing miR-497-5p.
J Cell Biochem. 121:1934–1944. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Cui X, Yu T, Shang J, Xiao D and Wang X:
Long Non-Coding RNA CDKN2B-AS1 facilitates laryngeal squamous cell
cancer through regulating miR-497/CDK6 Pathway. Onco Targets Ther.
12:8853–8862. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Yin Y, Long J, He Q, Li Y, Liao Y, He P
and Zhu W: Emerging roles of circRNA in formation and progression
of cancer. J Cancer. 10:5015–5021. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Gao Y, Zhang M, Xu B, Han L, Lan S, Chen
J, Dong Y and Cao L: Circular RNA expression profiles reveal that
hsa_circ_0018289 is up-regulated in cervical cancer and promotes
the tumorigenesis. Oncotarget. 8:86625–86633. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Adhikary J, Chakraborty S, Dalal S, Basu
S, Dey A and Ghosh A: Circular PVT1: An oncogenic non-coding RNA
with emerging clinical importance. J Clin Pathol. 72:513–519. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Verduci L, Ferraiuolo M, Sacconi A, Ganci
F, Vitale J, Colombo T, Paci P, Strano S, Macino G, Rajewsky N and
Blandino G: The oncogenic role of circPVT1 in head and neck
squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD
transcription-competent complex. Genome Biol. 18:2372017.
View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Qin S, Zhao Y, Lim G, Lin H and Zhang X
and Zhang X: Circular RNA PVT1 acts as a competing endogenous RNA
for miR-497 in promoting non-small cell lung cancer progression.
Biomed Pharmacother. 111:244–250. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Mechtler P, Singhal R, Kichina JV, Bard
JE, Buck MJ and Kandel ES: MicroRNA analysis suggests an additional
level of feedback regulation in the NF-κB signaling cascade.
Oncotarget. 6:17097–17106. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Kong X, Duan L, Qian X, Xu D, Liu H, Zhu Y
and Qi J: Tumor-suppressive microRNA-497 targets IKKβ to regulate
NF-κB signaling pathway in human prostate cancer cells. Am J Cancer
Res. 5:1795–1804. 2015.PubMed/NCBI
|
|
104
|
Zhao B, Wang Y, Tan X, Ke K, Zheng X, Wang
F, Lan S, Liao N, Cai Z, Shi Y, et al: Inflammatory
Micro-environment contributes to stemness properties and metastatic
potential of HCC via the NF-κB/miR-497/SALL4 Axis. Mol Ther
Oncolytics. 15:79–90. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Huang C, Ma R, Yue J, Li N, Li Z and Qi D:
miR-497 Suppresses YAP1 and Inhibits Tumor Growth in Non-Small Cell
Lung Cancer. Cell Physiol Biochem. 37:342–352. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Zhang L, Yu Z, Xian Y and Lin X:
microRNA-497 inhibits cell proliferation and induces apoptosis by
targeting YAP1 in human hepatocellular carcinoma. FEBS Open Bio.
6:155–164. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Cheng H, Dong H, Feng J, Tian H, Zhang H
and Xu L: miR-497 inhibited proliferation, migration and invasion
of thyroid papillary carcinoma cells by negatively regulating YAP1
expression. Onco Targets Ther. 11:4711–4721. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Wu Z, Li X, Cai X, Huang C and Zheng M:
miR-497 inhibits epithelial mesenchymal transition in breast
carcinoma by targeting Slug. Tumour Biol. 37:7939–7950. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Lin D and Wu J: Hypoxia inducible factor
in hepatocellular carcinoma: A therapeutic target. World J
Gastroenterol. 21:12171–12178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Lan J, Xue Y, Chen H, Zhao S, Wu Z, Fang
J, Han C and Lou M: Hypoxia-induced miR-497 decreases glioma cell
sensitivity to TMZ by inhibiting apoptosis. FEBS Lett.
588:3333–3339. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Wu Z, Cai X, Huang C, Xu J and Liu A:
miR-497 suppresses angiogenesis in breast carcinoma by targeting
HIF-1α. Oncol Rep. 35:1696–1702. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Qiao W, Jia Z, Liu H, Liu Q, Zhang T, Guo
W, Li P, Deng M and Li S: Prognostic and clinicopathological value
of Twist expression in breast cancer: A meta-analysis. PLoS One.
12:e1861912017. View Article : Google Scholar
|
|
113
|
Liu A, Huang C, Cai X, Xu J and Yang D:
Twist promotes angiogenesis in pancreatic cancer by targeting
miR-497/VEGFA axis. Oncotarget. 7:25801–25814. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Gu YY, Liu XS, Huang XR, Yu XQ and Lan HY:
Diverse role of TGF-β in kidney disease. Front Cell Dev Biol.
8:1232020. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Jafarzadeh M, Soltani BM, Dokanehiifard S,
Kay M, Aghdami N and Hosseinkhani S: Experimental evidences for
hsa-miR-497-5p as a negative regulator of SMAD3 gene expression.
Gene. 586:216–221. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Liu J, Zhou Y, Shi Z, Hu Y, Meng T, Zhang
X, Zhang S and Zhang J: microRNA-497 modulates breast cancer cell
proliferation, invasion, and survival by targeting SMAD7. DNA Cell
Biol. 35:521–529. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Hu J, Xu J and Ge W: miR-497 enhances
metastasis of oral squamous cell carcinoma through SMAD7
suppression. Am J Transl Res. 8:3023–3031. 2016.PubMed/NCBI
|
|
118
|
Al-Hujaily EM, Tang Y, Yao DS, Carmona E,
Garson K and Vanderhyden BC: Divergent roles of PAX2 in the
etiology and progression of ovarian cancer. Cancer Prev Res
(Phila). 8:1163–1173. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Lin Z, Zhao J, Wang X, Zhu X and Gong L:
Overexpression of microRNA-497 suppresses cell proliferation and
induces apoptosis through targeting paired box 2 in human ovarian
cancer. Oncol Rep. 36:2101–2107. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Zhang Y, Zhang Z, Li Z, Gong D, Zhan B,
Man X and Kong C: MicroRNA-497 inhibits the proliferation,
migration and invasion of human bladder transitional cell carcinoma
cells by targeting E2F3. Oncol Rep. 36:1293–1300. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Han H, Du Y, Zhao W, Li S, Chen D, Zhang
J, Liu J, Suo Z, Bian X, Xing B and Zhang Z: PBX3 is targeted by
multiple miRNAs and is essential for liver tumour-initiating cells.
Nat Commun. 6:82712015. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Yu T, Zhang X, Zhang L, Wang Y, Pan H, Xu
Z and Pang X: MicroRNA-497 suppresses cell proliferation and
induces apoptosis through targeting PBX3 in human multiple myeloma.
Am J Cancer Res. 6:2880–2889. 2016.PubMed/NCBI
|
|
123
|
Ma S, Chan YP, Woolcock B, Hu L, Wong KY,
Ling MT, Bainbridge T, Webber D, Chan TH, Guan XY, et al: DNA
fingerprinting tags novel altered chromosomal regions and
identifies the involvement of SOX5 in the progression of prostate
cancer. Int J Cancer. 124:2323–2332. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Li G, Wang K, Wang J, Qin S, Sun X and Ren
H: miR-497-5p inhibits tumor cell growth and invasion by targeting
SOX5 in non-small-cell lung cancer. J Cell Biochem.
120:10587–10595. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Han L, Liu B, Jiang L, Liu J and Han S:
MicroRNA-497 downregulation contributes to cell proliferation,
migration, and invasion of estrogen receptor alpha negative breast
cancer by targeting estrogen-related receptor alpha. Tumour Biol.
37:13205–13214. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Waters PS, McDermott AM, Wall D, Heneghan
HM, Miller N, Newell J, Kerin MJ and Dwyer RM: Relationship between
circulating and tissue microRNAs in a murine model of breast
cancer. PLoS One. 7:e504592012. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Regazzo G, Terrenato I, Spagnuolo M,
Carosi M, Cognetti G, Cicchillitti L, Sperati F, Villani V,
Carapella C, Piaggio G, et al: A restricted signature of serum
miRNAs distinguishes glioblastoma from lower grade gliomas. J Exp
Clin Cancer Res. 35:1242016. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Murata M: Inflammation and cancer. Environ
Health Prev Med. 23:502018. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Du M, Shi D, Yuan L, Li P, Chu H, Qin C,
Yin C, Zhang Z and Wang M: Circulating miR-497 and miR-663b in
plasma are potential novel biomarkers for bladder cancer. Sci Rep.
5:104372015. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Zhang Y, Zhang D, Wang F, Xu D, Guo Y and
Cui W: Serum miRNAs panel (miR-16-2*, miR-195, miR-2861, miR-497)
as novel non-invasive biomarkers for detection of cervical cancer.
Sci Rep. 5:179422015. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Zou G, Wang R and Wang M: Clinical
response and prognostic significance of serum miR-497 expression in
colorectal cancer. Cancer Biomark. 25:11–18. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Shao X, Miao M, Xue J, Xue J, Ji X and Zhu
H: The Down-regulation of MicroRNA-497 contributes to cell growth
and cisplatin resistance through PI3K/Akt pathway in osteosarcoma.
Cell Physiol Biochem. 36:2051–2062. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Xu S, Fu G, Tao Z, OuYang J, Kong F, Jiang
B, Wan X and Chen K: miR-497 decreases cisplatin resistance in
ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget.
6:26457–26471. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Xu J, Wang T, Cao Z, Huang H, Li J, Liu W,
Liu S, You L, Zhou L, Zhang T and Zhao Y: miR-497 downregulation
contributes to the malignancy of pancreatic cancer and associates
with a poor prognosis. Oncotarget. 5:6983–6993. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Troppan K, Wenzl K, Pichler M, Pursche B,
Schwarzenbacher D, Feichtinger J, Thallinger GG, Beham-Schmid C,
Neumeister P and Deutsch A: miR-199a and miR-497 are associated
with better overall survival due to increased chemosensitivity in
diffuse large B-cell lymphoma patients. Int J Mol Sci.
16:18077–18095. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Tian F, Zhan Y, Zhu W, Li J, Tang M, Chen
X and Jiang J: MicroRNA-497 inhibits multiple myeloma growth and
increases susceptibility to bortezomib by targeting Bcl-2. Int J
Mol Med. 43:1058–1066. 2019.PubMed/NCBI
|
|
137
|
Poel D, Boyd LNC, Beekhof R, Schelfhorst
T, Pham TV, Piersma SR, Knol JC, Jimenez CR, Verheul HMW and
Buffart TE: Proteomic analysis of miR-195 and miR-497 replacement
reveals potential candidates that increase sensitivity to
oxaliplatin in MSI/P53wt colorectal cancer cells. Cells.
8:11112019. View Article : Google Scholar
|
|
138
|
Ma W, Kang Y, Ning L, Tan J, Wang H and
Ying Y: Identification of microRNAs involved in gefitinib
resistance of non-small-cell lung cancer through the insulin-like
growth factor receptor 1 signaling pathway. Exp Ther Med.
14:2853–2862. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Zhu D, Tu M, Zeng B, Cai L, Zheng W, Su Z
and Yu Z: Up-regulation of miR-497 confers resistance to
temozolomide in human glioma cells by targeting mTOR/Bcl-2. Cancer
Med. 6:452–462. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Pang P, Shi X, Huang W and Sun K: miR-497
as a potential serum biomarker for the diagnosis and prognosis of
osteosarcoma. Eur Rev Med Pharmacol Sci. 20:3765–3769.
2016.PubMed/NCBI
|
|
141
|
Svedman FC, Lohcharoenkal W, Bottai M,
Brage SE, Sonkoly E, Hansson J, Pivarcsi A and Eriksson H:
Extracellular microvesicle microRNAs as predictive biomarkers for
targeted therapy in metastastic cutaneous malignant melanoma. PLoS
One. 13:e2069422018. View Article : Google Scholar
|
|
142
|
Sandhu V, Bowitz Lothe IM, Labori KJ,
Lingjærde OC, Buanes T, Dalsgaard AM, Skrede ML, Hamfjord J,
Haaland T, Eide TJ, et al: Molecular signatures of mRNAs and miRNAs
as prognostic biomarkers in pancreatobiliary and intestinal types
of periampullary adenocarcinomas. Mol Oncol. 9:758–771. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Wong N, Khwaja SS, Baker CM, Gay HA,
Thorstad WL, Daly MD, Lewis JS Jr and Wang X: Prognostic microRNA
signatures derived from The Cancer Genome Atlas for head and neck
squamous cell carcinomas. Cancer Med. 5:1619–1628. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Feng J, Gu X, Liu L, Lu M, Ma X, Cao Y,
Jiang R, Wang B and Zhao Q: Prognostic role of microRNA-497 in
cancer patients: A Meta-analysis. J Cancer. 9:3334–3342. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Liu Z, Wu S, Wang L, Kang S, Zhao B, He F,
Liu X, Zeng Y and Liu J: Prognostic value of MicroRNA-497 in
various cancers: A systematic review and Meta-analysis. Dis
Markers. 2019:24912912019. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Department of Medical Administration,
National Health and Health Commission of the People's Republic of
China: Guidelines for diagnosis and treatment of primary liver
cancer in China (2019 edition). Zhonghua Gan Zang Bing Za Zhi.
28:112–128. 2020.(In Chinese). PubMed/NCBI
|
